Identification of a 20-Gene Expression-Based Risk Score as a Predictor of Clinical Outcome in Chronic Lymphocytic Leukemia PatientsElias Bou Samra(Institute for Regenerative Medicine & Biotherapy), Jérôme Moreaux(Hôpital Saint Eloi)BioMed Research InternationalJanuary 1, 201410.1155/2014/423174Cited by 20SaveCiteExport RISWatch citationsRelated PapersPRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs|Clinical Epigenetics|2018|47Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells|Cancers|2019|30